0001209191-15-069921.txt : 20150909 0001209191-15-069921.hdr.sgml : 20150909 20150909162857 ACCESSION NUMBER: 0001209191-15-069921 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20150904 FILED AS OF DATE: 20150909 DATE AS OF CHANGE: 20150909 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Arbuckle Stuart A CENTRAL INDEX KEY: 0001557290 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 151099157 MAIL ADDRESS: STREET 1: VERTEX PHARMACEUTICALS INCORPORATED STREET 2: 130 WAVERLY ST. CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2015-09-04 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001557290 Arbuckle Stuart A C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 0 1 0 0 EVP\Chief Commercial Officer Common Stock 2015-09-04 4 M 0 9063 53.74 A 136578 D Common Stock 2015-09-04 4 S 0 400 124.43 D 136178 D Common Stock 2015-09-04 4 S 0 5200 125.42 D 130978 D Common Stock 2015-09-04 4 S 0 3463 126.44 D 127515 D Common Stock 140 I 401(k) Stock Option (right to buy) 53.74 2015-09-04 4 M 0 9063 0.00 D 2022-09-03 Common Stock 9063 18125 D Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $124.43 (range $123.98 to $124.85). Open market sales reported on this line occurred at a weighted average price of $125.42 (range $124.99 to $125.98). Open market sales reported on this line occurred at a weighted average price of $126.44 (range $126.00 to $126.92). The option vests in 16 quarterly installments from 09/04/2012. Omar White, Attorney-In-Fact 2015-09-09